KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients

[1] Al-Mulla F(1998)Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality J Pathol 185 130-138

[2] Going JJ(2004)Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations Biochem Biophys Res Commun 325 784-791

[3] Sowden ET(2008)Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 1626-1634

[4] Winter A(2008)Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer J Clin Oncol 26 4217-4219

[5] Pickford IR(2010)Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases Clin Cancer Res 16 790-799

[6] Birnie GD(2011)External Quality Assessment for KRAS Testing Is Needed: Setup of a European Program and Report of the First Joined Regional Quality Assessment Rounds The Oncologist 16 467-478

[7] Albanese I(2007)Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies Cancer Res 67 2643-2648

[8] Scibetta AG(2009)KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis PLoS One 4 e8199-1820

[9] Migliavacca M(2010)Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab JAMA 304 1812-5712

[10] Russo A(2008)Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer J Clin Oncol 26 5705-4835

[1] Al-Mulla F(1998)Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality J Pathol 185 130-138

[2] Going JJ(2004)Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations Biochem Biophys Res Commun 325 784-791

[3] Sowden ET(2008)Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 1626-1634

[4] Winter A(2008)Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer J Clin Oncol 26 4217-4219

[5] Pickford IR(2010)Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases Clin Cancer Res 16 790-799

[6] Birnie GD(2011)External Quality Assessment for KRAS Testing Is Needed: Setup of a European Program and Report of the First Joined Regional Quality Assessment Rounds The Oncologist 16 467-478

[7] Albanese I(2007)Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies Cancer Res 67 2643-2648

[8] Scibetta AG(2009)KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis PLoS One 4 e8199-1820

[9] Migliavacca M(2010)Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab JAMA 304 1812-5712

[10] Russo A(2008)Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer J Clin Oncol 26 5705-4835